Compare NBIX & AEIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | AEIS |
|---|---|---|
| Founded | 1992 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.8B |
| IPO Year | 1996 | 1996 |
| Metric | NBIX | AEIS |
|---|---|---|
| Price | $158.25 | $325.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 11 |
| Target Price | $180.91 | ★ $307.73 |
| AVG Volume (30 Days) | ★ 1.2M | 762.1K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.11% |
| EPS Growth | 41.95 | ★ 168.53 |
| EPS | ★ 1.91 | 1.58 |
| Revenue | $161,626,000.00 | ★ $453,095,000.00 |
| Revenue This Year | $24.73 | $22.53 |
| Revenue Next Year | $13.14 | $13.38 |
| P/E Ratio | ★ $83.53 | $219.29 |
| Revenue Growth | ★ 977.51 | 38.39 |
| 52 Week Low | $117.84 | $112.25 |
| 52 Week High | $162.39 | $397.44 |
| Indicator | NBIX | AEIS |
|---|---|---|
| Relative Strength Index (RSI) | 75.63 | 38.34 |
| Support Level | $125.54 | $292.26 |
| Resistance Level | $158.92 | $355.00 |
| Average True Range (ATR) | 4.50 | 16.23 |
| MACD | 2.55 | -6.25 |
| Stochastic Oscillator | 89.50 | 3.26 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Advanced Energy Industries Inc provides precision power conversion, measurement, and control solutions. The company designs, manufactures, sells, and services power electronics conversion products that transform raw electrical power into controllable, usable power for complex equipment. It operates in one reporting segment, Power Electronics Conversion Products, serving the Semiconductor Equipment, Data Center Computing, Industrial and Medical, and Telecom and Networking markets. Its products include Plasma Power Products, AC-DC Power Supply Units, DC-DC Converters, High Voltage solutions, SCR Power Controllers, and Sense and Measurement solutions. The company operates in the United States, Asia, Europe, and other regions.